<unk>  is used to treat hormone-sensitive cancers of the prostate in men and uterine fibroids in women. In addition,<unk>  has been proven to be highly effective in treating central precocious puberty in children. It is available as a daily intramuscular injection.<unk>  is also available in a 12-month subcutaneous implant (Vantas) for the palliative treatment of advanced prostate cancer, since 2005 in the US, and since Jan 2010 in the UK. A 12-month subcutaneous implant (Supprelin LA) for central precocious puberty (CPP) was approved on May 3, 2007 by the U.S. Food and Drug Administration.<unk>  can be part of the primary care protocol in transgender children/youth, which is an off-label use in the USA and the UK, and is used in suppressing cis-sex puberty, until the patient is ready to begin cross-sex hormonal therapy. It is also sometimes prescribed to transgender adults who benefit from having their sex hormone production halted.
Histrelin
Ghrelin
Incretin
Somatostatin
Nesfatin-1
Agouti-related peptide
Beta-Endorphin
Prolactin-releasing peptide